Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
Autor: | Paige A. Armstrong, Alison M. Binder |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Epidemiology Science Population Patient characteristics History 21st Century Article Antimicrobial therapy Young Adult Internal medicine medicine Humans Public Health Surveillance Practice Patterns Physicians' Medical prescription Child education Doxycycline education.field_of_study Insurance Health Multidisciplinary business.industry Disease Management Rickettsia Infections Middle Aged medicine.disease United States Spotted fever Rickettsiosis Child Preschool Ehrlichiosis (canine) Infectious diseases Medicine Female Disease Susceptibility Bacterial infection business Typhus medicine.drug |
Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) Scientific Reports |
ISSN: | 2045-2322 |
Popis: | Rickettsial diseases (RDs) are transmitted to humans by ectoparasites, including ticks and fleas. Symptoms range from mild febrile illness, to severe disease or death. Doxycycline is the treatment of choice for patients of all ages; early treatment based on clinical diagnosis is critical to prevent severe outcomes. We conducted a descriptive analysis using insurance claims data captured by IBM MarketScan® research databases to describe demographics, treatment patterns, and outcomes of patients diagnosed with RDs in the United States during 2005–2017. Overall, 14,830 patients had a RD diagnosis during 2005–2017; 7,517 (50.7%) spotted fever rickettsiosis (SFR), 4,571 ( 30.8%) ehrlichiosis, 1,362 (9.2%) typhus group rickettsiosis (TGR), and 1,193 (8.0%) other rickettsial diseases. Among all patients diagnosed, 53.1% received doxycycline. Prescription rates varied by diagnosis and age; 24.1% of TGR and 61.1% of SFR patients received doxycycline; 23.9% of persons |
Databáze: | OpenAIRE |
Externí odkaz: |